Format

Send to

Choose Destination
Mol Cancer Ther. 2017 Nov;16(11):2618-2626. doi: 10.1158/1535-7163.MCT-17-0292. Epub 2017 Aug 23.

Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia.

Author information

1
Department of Food Science, University of Guelph, Guelph, Ontario, Canada.
2
School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
3
Grand River Cancer Centre, Kitchener, Ontario, Canada.
4
Department of Biology, University of Waterloo, Waterloo, Ontario, Canada.
5
Princess Margaret Cancer Center, Ontario Cancer Institute, Toronto, Ontario, Canada.
6
Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
7
Department of Food Science, University of Guelph, Guelph, Ontario, Canada. paul.spagnuolo@uoguelph.ca.

Abstract

Acute myeloid leukemia (AML) is a devastating disease characterized by poor patient outcome and suboptimal chemotherapeutics. Here, a high-throughput screen identified diosmetin, a citrus flavonoid, with anti-AML activity. Diosmetin imparted selective toxicity against leukemia and leukemia stem cells in vitro and in vivo with no effect on normal hematopoietic stem cells. Mechanistically, we demonstrated that diosmetin targets estrogen receptor (ER) β. ERβ expression conferred cell sensitivity, as patient-derived AML cells with high levels of ERβ were sensitive, whereas cells with low ERβ were insensitive to diosmetin. Knockdown of ERβ confirmed resistance, whereas overexpression enhanced sensitivity to diosmetin, which was demonstrated to be mediated by reactive oxygen species signaling. In summary, these studies highlight targeting of ERβ with diosmetin as a potential novel therapeutic strategy for the treatment of AML. Mol Cancer Ther; 16(11); 2618-26. ©2017 AACR.

PMID:
28835383
DOI:
10.1158/1535-7163.MCT-17-0292
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center